Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.10
+0.07003.45%
Post-market: 2.100.00000.00%16:15 EDT
Volume:622.92K
Turnover:1.32M
Market Cap:151.65M
PE:-1.28
High:2.17
Open:2.02
Low:2.00
Close:2.03
52wk High:3.60
52wk Low:1.50
Shares:72.21M
Float Shares:37.05M
Volume Ratio:0.75
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:2.65
PE(LYR):-1.05

Loading ...

Acumen presents new findings at AAIC conference

TIPRANKS
·
Jul 15

Acumen Says EBD Candidate Acu401 Boosts Brain Exposure up to 40-fold in Primate Study

Reuters
·
Jul 15

Acumen Pharmaceuticals - Ebd Bispecific Antibodies Show Improved Brain Penetration Compared to Native Anti-aβo Antibodies

THOMSON REUTERS
·
Jul 15

Acumen Pharmaceuticals - no Hematological Safety Signals Observed for Acu401 in Non-human Primates

THOMSON REUTERS
·
Jul 15

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

GlobeNewswire
·
Jul 15

Acumen Pharmaceuticals to Present Enhanced Brain Delivery Alzheimer’s Data at AAIC 2026

Reuters
·
Jul 07

Acumen Pharmaceuticals Insider Makes Eye-Catching Stock Move

TIPRANKS
·
Jun 18

Acumen Pharma director Derrell Porter disposes of USD 45,128 in common shares

Reuters
·
Jun 18

BRIEF-JCR Says Acumen Exercises Exclusive Option For Up To Two Alzheimer's Candidates

Reuters
·
Jun 18

JCR announces Acumen exercises exclusive option for Alzheimer’s candidates

TIPRANKS
·
Jun 18

Jcr Pharmaceuticals Co - to Receive Tiered Royalties on Net Sales From Collaboration Products

THOMSON REUTERS
·
Jun 18

Jcr Pharmaceuticals Co - Eligible for up to $555 Mln in Milestone Payments From Acumen Deal

THOMSON REUTERS
·
Jun 18

Acumen Pharmaceuticals Nominates 2 Drug Candidates to Treat Alzheimer's Disease

MT Newswires Live
·
Jun 16

Acumen nominates two development candidates in EBD program

TIPRANKS
·
Jun 16

Acumen nominates ACU301, ACU401 Enhanced Brain Delivery Alzheimer’s candidates, targets mid-2027 IND filing

Reuters
·
Jun 16

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (Ebd™) Development Candidates for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
Jun 16

Acumen Pharma director Nathan B. Fountain sells 6,400 shares worth $14,273

Reuters
·
Jun 11

Acumen Stockholders Approve Directors and Equity Incentive Plan

TIPRANKS
·
Jun 04

Acumen Pharmaceuticals shareholders approve amended 2021 equity incentive plan

Reuters
·
Jun 04

Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price

TIPRANKS
·
May 14